New targeted treatments for patients with PNH, such as the complement C3 inhibitor pegcetacoplan, have demonstrated significant and meaningful improvements in haematological and clinical parameters in patients with PNH. Here, C3 is linked to paroxysmal nocturnal hemoglobinuria.